Harisha Kadali
Takeda (United States)(US)
Publications by Year
Research Areas
Inflammatory Bowel Disease, Microscopic Colitis, Sleep and Wakefulness Research, Biosimilars and Bioanalytical Methods, Sleep and related disorders
Most-Cited Works
- → Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1(2023)82 cited
- → Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn’s Disease (EXPLORER)(2023)80 cited
- → Pharmacokinetics, Safety and Efficacy of Intravenous Vedolizumab in Paediatric Patients with Ulcerative Colitis or Crohn’s Disease: Results from the Phase 2 HUBBLE Study(2022)42 cited
- → Oveporexton, an Oral Orexin Receptor 2–Selective Agonist, in Narcolepsy Type 1(2025)28 cited
- → Vedolizumab Concentrations in Breast Milk: Results from a Prospective, Postmarketing, Milk-Only Lactation Study in Nursing Mothers with Inflammatory Bowel Disease(2021)11 cited
- → Impact of Concomitant 5-Aminosalicylic Acid Therapy on Vedolizumab Efficacy and Safety in Inflammatory Bowel Disease: Post Hoc Analyses of Clinical Trial Data(2023)10 cited
- → Assessment of Vedolizumab Disease‐Drug‐Drug Interaction Potential in Patients With Inflammatory Bowel Diseases(2020)7 cited
- → TAK-994 mechanistic investigation into drug-induced liver injury(2025)7 cited
- → 885: TRIPLE COMBINATION THERAPY WITH VEDOLIZUMAB, ADALIMUMAB, AND METHOTREXATE IN PATIENTS WITH HIGH-RISK CROHN'S DISEASE: INTERIM ANALYSIS FROM THE OPEN-LABEL, PHASE 4 EXPLORER TRIAL(2022)5 cited
- → S0876 Assessment of Vedolizumab Disease-Drug-Drug Interaction in Patients With Inflammatory Bowel Diseases(2020)1 cited